Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-08-23
2011-08-23
Bradley, Christina (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C514S002700, C514S021100
Reexamination Certificate
active
08003602
ABSTRACT:
This invention relates to a novel purified compound PM181104, of formula:of molecular weight 1514 and molecular formula C69H66N18O13S5; which is obtained by fermentation of the microorganism belonging toKocuriaspecies (ZMA B-1/MTCC 5269). The invention includes all stereoisomeric forms and all tautomeric forms of the compound PM181104 and pharmaceutically acceptable salts and derivatives such as esters and ethers. The present invention further relates to processes for the production of the novel antibacterial compound(s), to the production of the microorganism belonging toKocuriaspecies (ZMA B-1/MTCC 5269), and to pharmaceutical compositions containing the novel compound(s) as an active ingredient and its/their use in medicines for treatment and prevention of diseases caused by bacterial infections.
REFERENCES:
patent: 7022667 (2006-04-01), Hudyma et al.
Cohen, M. “Antimicrobial resistance: prognosis for public health”, Trends in Microbiology, vol. 2, No. 10, Oct. 1994, pp. 422-425.
Aeschlimann, J. et al. “Pharmacodynamic Analysis of the Activity of Quinupristin-Dalfopristin against Vancomycin-ResistantEnterococcus faeciumwith Differing MBCs via Time-Kill-Curve and Postantibiotic Effect Methods”, Antimicrobial Agents and Chemotherapy, vo. 42, Sep. 1998, pp. 2188-2192.
Livermore, D. “Bacterial Resistance: Origins, Epidemiology, and Impact”, Bacterial Resistance-CID, Supplement I, vol. 36, 2003, S11-S23.
Mutnick, A. et al., “Linezolid Resistance Since 2001: SENTRY Antimicrobial Surveillance Program”, The Annals of Pharmacotherapy, vol. 37, Jun. 2003, pp. 769-774.
Canu, A. et al. “Overcoming Bacterial Resistance by Dual Target Inhibition: The Case of Streptogramins”, Current Drug Targets-Infectious Disorders, vol. I, 2001, pp. 215-225.
Mathew, A. et al. “Synthesis and Evaluation of Some Water-Soluble Prodrugs and Derivatives of Taxol with Antitumor Activity”, J. Med Chem, vol. 35, 1992, pp. 145-151.
Saulnier, Mark et al. “Synthesis of Etoposide Phosphate, BMY-40481: A Water-Soluble Clinically Active Prodrug of Etoposide”, Bioorganic & Medicinal Chemistry Letters, vol. 4, No. 21, 1994, pp. 2567-2572.
Von Hunolstein, C. et al. “Penicillin tolerance amongst non-toxigenicCorynebacterium diphtheriaeisolated from cases of pharyngitis”, Journal of Antimicrobial Chemotherapy, vol. 50, 2002, pp. 125-128.
Baltz, R. et al. “Natural Products to drugs: daptomycin and related lipopeptide antibiotics”, Natural Product Report, vol. 22, Dec. 2005, pp. 717-741.
March, J., “Advanced Organic Chemistry”. 1992, 4thEdition, pp. 393-398.
March, J., “Ethers”, pp. 389-390 and 654-655.
D'Souza Lisette
Devi Prabha
Eyyammadichiyil Sreekumar Sankaranarayanan
George Saji David
Krishna Sridevi
Bradley Christina
Council of Scientific and Industrial Research
Hamre Schumann Mueller & Larson P.C.
Piramal Life Sciences Limited
LandOfFree
Antibacterial compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibacterial compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibacterial compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2741037